The story of the erectile dysfunction drug presents a challenging picture for investors. While the initial release generated significant gains, the lapse of its patent opened the avenue to cheaper competitors, dramatically reducing market share. This creates a unique risk for drug manufacturers depending on comparable blockbuster medications, sugge

The story of Viagra, and its creator copyright, presents a challenging case study for investors. Initially a blockbuster drug, yielding billions in revenue , its exclusivity period created a wave of knock-off medications, significantly impacting its dominance. While some pharmaceutical companies may attempt to capitalize on related treatments , the